Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 406 to 420 of 449 results for cardiovascular disease

  1. Myocardial perfusion scintigraphy for the diagnosis and management of angina and myocardial infarction (TA73)

    Evidence-based recommendations on myocardial perfusion scintigraphy for diagnosing and managing angina and myocardial infarction in adults.

    Technology appraisal guidance
    Last updated
    1 July 2011
    View recommendations

    Sections for TA73

  2. Rituximab for the treatment of relapsed or refractory chronic lymphocytic leukaemia (TA193)

    Evidence-based recommendations on rituximab for treating relapsed or refractory chronic lymphocytic leukaemia in adults.

    Technology appraisal guidance
    Published
    28 July 2010
    View recommendations

    Sections for TA193

  3. Procalcitonin testing for diagnosing and monitoring sepsis (ADVIA Centaur BRAHMS PCT assay, BRAHMS PCT Sensitive Kryptor assay, Elecsys BRAHMS PCT assay, LIAISON BRAHMS PCT assay and VIDAS BRAHMS PCT assay) (HTG386)

    Evidence-based recommendations on procalcitonin testing for diagnosing and monitoring sepsis (ADVIA Centaur BRAHMS PCT assay, BRAHMS PCT Sensitive Kryptor assay, Elecsys BRAHMS PCT assay, LIAISON BRAHMS PCT assay and VIDAS BRAHMS PCT assay).

    HealthTech guidance
    Published
    7 October 2015

    Sections for HTG386

  4. Percutaneous mitral valve leaflet repair for mitral regurgitation (HTG513)

    Evidence-based recommendations on percutaneous mitral valve leaflet repair for mitral regurgitation in adults. This involves attaching a clip to the leaflets of the mitral valve.

    HealthTech guidance
    Published
    29 May 2019
    View recommendations

    Sections for HTG513

  5. Vadadustat for treating symptomatic anaemia in adults having dialysis for chronic kidney disease (TA1035)

    Evidence-based recommendations on vadadustat (Vafseo) for treating symptomatic anaemia in adults having dialysis for chronic kidney disease.

    Technology appraisal guidance
    Published
    23 January 2025
    View recommendations

    Sections for TA1035

  6. Intramuscular diaphragm stimulation for ventilator-dependent chronic respiratory failure caused by motor neurone disease (HTG450)

    Evidence-based recommendations on intramuscular diaphragm stimulation for ventilator-dependent chronic respiratory failure in people with motor neurone disease. This involves implanting electrodes into the diaphragm to make it contract. This gradually strengthens the diaphragm and may eventually help the person to breathe without a ventilator.

    HealthTech guidance
    Published
    27 September 2017
    View recommendations

    Sections for HTG450

  7. Sodium zirconium cyclosilicate for treating hyperkalaemia (TA1148)

    Evidence-based recommendations on sodium zirconium cyclosilicate (Lokelma) for treating hyperkalaemia in adults.

    Technology appraisal guidance
    Published
    29 April 2026
    View recommendations

    Sections for TA1148

  8. Percutaneous atherectomy of femoropopliteal arterial lesions with plaque excision devices (HTG251)

    Evidence-based recommendations on percutaneous atherectomy of femoropopliteal arterial lesions with plaque excision devices. This involves using a special cutting device to remove excess debris inside diseased blood vessels.

    HealthTech guidance
    Published
    23 February 2011
    View recommendations

    Sections for HTG251

  9. Coronary revascularisation: Cangrelor (ESNM63)

    Summary of the evidence on cangrelor for coronary revascularisation to inform local NHS planning and decision-making

    Evidence summary
    Published
    3 November 2015

  10. CytoSorb for reducing risk of bleeding during cardiac surgery (MIB249)

    NICE has developed a medtech innovation briefing (MIB) on CytoSorb for reducing risk of bleeding during cardiac surgery .

    Medtech innovation briefing
    Published
    2 February 2021

  11. What is the most clinically and cost-effective tool for diagnosing peripheral arterial disease in people with diabetes?

    arterial disease in people with diabetes? Any explanatory notes(if applicable) People with diabetes are at higher risk of...

    Research recommendation
    Published
    22 January 2021

  12. Evidence on the efficacy of bioresorbable stent implantation to treat coronary artery disease is inadequate. Evidence on its safety has shown an increased risk of serious complications in the longer term. This includes an increased risk of myocardial infarction and death with some types of bioresorbable stents. Therefore, this procedure should only be used in the context of research. Find out what only in research means on the NICE interventional procedures guidance page.

    the efficacy of bioresorbable stent implantation to treat coronary artery disease is inadequate. Evidence on its safety has shown an...

    Research recommendation
    Published
    7 September 2022

  13. Detecting, managing and monitoring haemostasis: viscoelastometric point‑of‑care testing (ROTEM, TEG and Sonoclot systems) (HTG348)

    Evidence-based recommendations on viscoelastometric point-of-care testing devices (the ROTEM, TEG and Sonoclot systems).

    HealthTech guidance
    Published
    20 August 2014
    View recommendations

    Sections for HTG348

  14. Air pollution: outdoor air quality and health (NG70)

    This guideline covers road-traffic-related air pollution and its links to ill health. It aims to improve air quality and so prevent a range of health conditions and deaths.

    NICE guideline
    Published
    30 June 2017
    View recommendations

    Sections for NG70

  15. Evidence summaries: new medicines – Integrated process statement (PMG11)

    This integrated process statement has been produced to explain how 'Evidence summaries: new medicines' (ESNMs) are developed. It provides an overview of the key process principles and describes all stages of the development of ESNMs